Loading
A phase 3 trial of Trastuzumab deruxtecan, Bevacizumab in ovarian cancer, run by Daiichi Sankyo, now recruiting.
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) is a phase 3 interventional study registered as NCT06819007 by Daiichi Sankyo, with 582 participants planned, started 2025-03-19 and due to reach its primary completion in 2028-11-01. Interventions recorded: Trastuzumab Deruxtecan, Bevacizumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).